Bacterial inclusion bodies as potential synthetic devices for pathogen recognition and a therapeutic substance release

Microbial Cell Factories

Volumn 12, Issue 1, 2013, Pages

  Talafová, Klaudia ^a   Hrabárová, Eva ^a   Chorvát, Dušan ^b   Nahálka, Jozef ^a  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

^b INTERNATIONAL LASER CENTER   (Slovakia)

Author keywords

Drug release; Nanopills; Pathogen targeting

Indexed keywords

ADHESIN; GLUTARALDEHYDE; INTEIN; LYSINE; NANOMATERIAL; PROTEIN; SIALIC ACID; SORTASE;

ARTICLE; CELL INCLUSION; CONTROLLED STUDY; ERYTHROCYTE; HELICOBACTER PYLORI; HYDROPHOBICITY; IN VITRO STUDY; MICROORGANISM DETECTION; NONHUMAN; PROTEIN AGGREGATION; PROTEIN EXPRESSION;

ADHESINS, BACTERIAL; AMINOACYLTRANSFERASES; BACTERIA; BACTERIAL PROTEINS; CYSTEINE ENDOPEPTIDASES; ERYTHROCYTES; ESCHERICHIA COLI PROTEINS; GLUTARAL; HELICOBACTER PYLORI; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INCLUSION BODIES; LYSINE; NANOSTRUCTURES;

BACTERIA (MICROORGANISMS); HELICOBACTER PYLORI;

EID: 84873346511     PISSN: None     EISSN: 14752859     Source Type: Journal    
DOI: 10.1186/1475-2859-12-16     Document Type: Article

References (35)

1. Karlsson KA. Meaning and therapeutic potential of microbial recognition of host glycoconjugates. Mol Microbiol 1998, 29:1-11. 10.1046/j.1365-2958.1998.00854.x, 9701797.
2. Sharon N. Carbohydrates as future anti-adhesion drugs for infectious diseases. Biochim Biophys Acta 2006, 1760:527-537. 10.1016/j.bbagen.2005.12.008, 16564136.
3. Aspholm M, Olfat FO, Nordén J, Sondén B, Lundberg C, Sjöström R, Altraja S, Odenbreit S, Haas R, Wadström T, Engstrand L, Semino-Mora C, Liu H, Dubois A, Teneberg S, Arnqvist A, Borén T. SabA is the H. pylori hemagglutinin and is polymorphic in binding to sialylated glycans. PLoS Pathog 2006, 2:0989-1001.
4. Backert S, Clyne M. Pathogenesis of Helicobacter pylori infection. Helicobacter 2011, 16(SUPPL. 1):19-25.
5. Moran AP, Gupta A, Joshi L. Sweet-talk: Role of host glycosylation in bacterial pathogenesis of the gastrointestinal tract. Gut 2011, 60:1412-1425. 10.1136/gut.2010.212704, 21228430.
6. Du J, Yarema KJ. Carbohydrate engineered cells for regenerative medicine. Adv Drug Deliv Rev 2010, 62:671-682. 10.1016/j.addr.2010.01.003, 3032398, 20117158.
7. El-Boubbou K, Huang X, . Glyco-nanomaterials Translating insights from the sugar-code to biomedical applications. Curr Med Chem 2011, 18:2060-2078. 10.2174/092986711795656144, 21517769, Glyco-nanomaterials.
8. García-Fruitós E, Vázquez E, Díez-Gil C, Corchero JL, Seras-Franzoso J, Ratera I, Veciana J, Villaverde A. Bacterial inclusion bodies: Making gold from waste. Trends Biotechnol 2012, 30:65-70. 10.1016/j.tibtech.2011.09.003, 22037492.
9. Worrall DM, Goss NH. The formation of biologically active beta-galactosidase inclusion bodies in Escherichia coli. Aust J Biotechnol 1989, 3:28-32.
10. Tokatlidis K, Dhurjati P, Millet J, Beguin P, Aubert JP. High activity of inclusions bodies formed in Escherichia coli overproducing clostridium thermocellum endoglucanase D. FEBS Lett 1991, 282:205-208. 10.1016/0014-5793(91)80478-L, 2026260.
11. García-Fruitós E, González-Montalbán N, Morell M, Vera A, Ferraz RM, Arís A, Ventura S, Villaverde A. Aggregation as bacterial inclusion bodies does not imply inactivation of enzymes and fluorescent proteins. Microb Cell Fact 2005, 4:27. 10.1186/1475-2859-4-27, 1224866, 16156893.
12. Nahálka J, Nidetzky B. Fusion to a pull-down domain: A novel approach of producing Trigonopsis variabilis D-amino acid oxidase as insoluble enzyme aggregates. Biotechnol Bioeng 2007, 97:454-461. 10.1002/bit.21244, 17089401.
13. Nahálka J, Vikartovská A, Hrabárová E. A crosslinked inclusion body process for sialic acid synthesis. J Biotechnol 2008, 134:146-153. 10.1016/j.jbiotec.2008.01.014, 18313163.
14. Nahálka J, Pätoprstý V. Enzymatic synthesis of sialylation substrates powered by a novel polyphosphate kinase (PPK3). Org Biomol Chem 2009, 7:1778-1780. 10.1039/b822549b, 19590770.
15. García-Fruitós E, Rodríguez-Carmona E, Díez-Gil C, Ferraz RM, Vázquez E, Corchero JL, Cano-Sarabia M, Ratera I, Ventosa N, Veciana J, Villaverde A. Surface cell growth engineering assisted by a novel bacterial nanomaterial. Adv Mater 2009, 21:4249-4253.
16. Díez-Gil C, Krabbenborg S, García-Fruitós E, Vazquez E, Rodríguez-Carmona E, Ratera I, Ventosa N, Seras-Franzoso J, Cano-Garrido O, Ferrer-Miralles N, Villaverde A, Veciana J. The nanoscale properties of bacterial inclusion bodies and their effect on mammalian cell proliferation. Biomaterials 2010, 31:5805-5812. 10.1016/j.biomaterials.2010.04.008, 20452667.
17. Villaverde A, García-Fruitós E, Rinas U, Seras-Franzoso J, Kosoy A, Corchero JL, Vazquez E. Packaging protein drugs as bacterial inclusion bodies for therapeutic applications. Microb Cell Fact 2012, 11:76. 10.1186/1475-2859-11-76, 3538617, 22686540.
18. Vázquez E, Corchero JL, Burgueño JF, Seras-Franzoso J, Kosoy A, Bosser R, Mendoza R, Martínez-Láinez JM, Rinas U, Fernández E, Ruiz-Avila L, García-Fruitõs E, Villaverde A. Functional inclusion bodies produced in bacteria as naturally occurring nanopills for advanced cell therapies. Adv Mater 2012, 24:1742-1747. 10.1002/adma.201104330, 22410789.
19. Liovic M, Ozir M, Zavec AB, Peternel S, Komel R, Zupancic T. Inclusion bodies as potential vehicles for recombinant protein delivery into epithelial cells. Microb Cell Fact 2012, 11:67. 10.1186/1475-2859-11-67, 3434093, 22624805.
20. Talafová K, Nahálka J. In situ monitoring of in vitro sialylation by inclusion bodies. J Glycomics Lipidomics 2012, 2:3.
21. Mao H. A self-cleavable sortase fusion for one-step purification of free recombinant proteins. Protein Expr Purif 2004, 37:253-263. 10.1016/j.pep.2004.06.013, 15294306.
22. Zhao Z, Lu W, Dun B, Jin D, Ping S, Zhang W, Chen M, Xu M, Lin M. Purification of green fluorescent protein using a two-intein system. Appl Microbiol Biotechnol 2008, 77:1175-1180. 10.1007/s00253-007-1233-0, 17973109.
23. Migneault I, Dartiguenave C, Bertrand MJ, Waldron KC. Glutaraldehyde: Behavior in aqueous solution, reaction with proteins, and application to enzyme crosslinking. Biotechniques 2004, 37:790-802.
24. Sakai H, Hara H, Yuasa M, Tsai AG, Takeoka S, Tsuchida E, Intaglietta M. Molecular dimensions of Hb-based O2 carriers determine constriction of resistance arteries and hypertension. Am J Physiol Heart Circ Physiol 2000, 279:H908-H915.
25. Lo Schiavo V, Robert P, Limozin L, Bongrand P. Quantitative modeling assesses the contribution of bond strengthening, rebinding and force sharing to the avidity of biomolecule interactions. PLoS One 2012, 7:e44070. 10.1371/journal.pone.0044070, 3443103, 23024747.
26. Matthews BW. Hydrophobic interactions in proteins 2001, Chichester: eLS. John Wiley & Sons Ltd, http://www.els.net/WileyCDA/ElsArticle/refId-a0002975.html.
27. Nahálka J, Mislovičová D, Kavcová H. Targeting lectin activity into inclusion bodies for the characterisation of glycoproteins. Mol Biosyst 2009, 5:819-821. 10.1039/b900526a, 19603115.
28. Margreiter G, Messner P, Caldwell KD, Bayer K. Size characterization of inclusion bodies by sedimentation field-flow fractionation. J Biotechnol 2008, 138:67-73. 10.1016/j.jbiotec.2008.07.1995, 18760314.
29. Peternel T, Komel R. Isolation of biologically active nanomaterial (inclusion bodies) from bacterial cells. Microb Cell Fact 2010, 9:66. 10.1186/1475-2859-9-66, 2944166, 20831775.
30. Tachev KD, Danov KD, Kralchevsky PA. On the mechanism of stomatocyte-echinocyte transformations of red blood cells: experiment and theoretical model. Colloids Surf B Biointerfaces 2004, 34:123-140. 10.1016/j.colsurfb.2003.12.011, 15261082.
31. Matsunaga S, Matsuoka K, Shimizu K, Endo Y, Sawasaki T. Biotinylated-sortase self-cleavage purification (BISOP) method for cell-free produced proteins. BMC Biotechnol 2010, 10:42. 10.1186/1472-6750-10-42, 2901362, 20525307.
32. Xing L, Wu W, Zhou B, Lin Z. Streamlined protein expression and purification using cleavable self-aggregating tags. Microb Cell Fact 2011, 10:42. 10.1186/1475-2859-10-42, 3124420, 21631955.
33. Trivedi R, Kompella UB. Nanomicellar formulations for sustained drug delivery: Strategies and underlying principles. Nanomedicine 2010, 5:485-505. 10.2217/nnm.10.10, 2902878, 20394539.
34. Leekha S, Terrell CL, Edson RS. General principles of antimicrobial therapy. Mayo Clin Proc 2011, 86:156-167. 10.4065/mcp.2010.0639, 3031442, 21282489.
35. Siegel RA, Rathbone MJ. Overview of controlled release mechanisms. Fundamentals and Applications of Controlled Release Drug delivery 2012, 19-43. Springer. Advances in Delivery Science and Technology, Siepmann J, Siegel RA, Rathbone MJ, 1.